The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized trial of FOLFOX alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient DNA mismatch repair or microsatellite instability (ATOMIC, Alliance A021502).
 
Frank A. Sinicrope
Stock and Other Ownership Interests - Gilead Sciences; illumina
Consulting or Advisory Role - EMD Serono; Ventana Medical Systems
Travel, Accommodations, Expenses - ventana medical systems
 
Fang-Shu Ou
No Relationships to Disclose
 
Qian Shi
No Relationships to Disclose
 
Andrew B. Nixon
Consulting or Advisory Role - Cerulean Pharma; Novartis; Pfizer
Research Funding - Acceleron Pharma; Amgen; Genentech/Roche; Incyte; medpacto; Novartis; Seagen; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Patent Pending (Inst); Patent pending (Inst)
 
Kabir Mody
Consulting or Advisory Role - Celgene; Genentech/Roche; Merrimack
Research Funding - ARIAD; FibroGen; MedImmune; Senhwa Biosciences; TRACON Pharma
 
Alexandra Levasseur
No Relationships to Disclose
 
Amylou C. Dueck
Consulting or Advisory Role - Algeta/Bayer; Bayer; Bayer
 
Asha R. Dhanarajan
No Relationships to Disclose
 
Christopher Hanyoung Lieu
Consulting or Advisory Role - Merck; Merrimack
Other Relationship - Immune Design
 
Deirdre Jill Cohen
No Relationships to Disclose
 
Federico Innocenti
No Relationships to Disclose
 
Robert J. Behrens
No Relationships to Disclose
 
Walter Peters
No Relationships to Disclose
 
Daniel J. Sargent
Consulting or Advisory Role - Abbvie; Acerta Pharma; ARIAD; Astellas Pharma; AstraZeneca/MedImmune; Biothera; Celldex; Exelixis; Genentech; Incyte; Kyowa Hakko Kirin; Medivation; Merck; Merrimack; Nektar; Novartis; Pharmacyclics; Pique; Spiration; Xbiotech
Research Funding - Celgene (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Celgene
 
Nicolas Sommer
No Relationships to Disclose
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Aduro Biotech; Agios (I); ASLAN Pharmaceuticals (I); Astellas Pharma (I); AstraZeneca (I); Bayer (I); Blueprint Medicines (I); Boston Scientific (I); Bristol-Myers Squibb; Bristol-Myers Squibb (I); CASI Pharmaceuticals (I); Celgene; Celsion (I); Delcath Systems (I); Eisai (I); Gilead Sciences; Halozyme (I); IntegraGen (I); Ipsen (I); Janssen; MedImmune; Merck (I); Merrimack; New B Innovation (I); Newlink Genetics; Onxeo (I); Sanofi; Servier (I); Silenseed; Sillajen (I); Sirtex Medical (I); VAXIMM; Vicus Therapeutics; Westhaven (I)
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Incyte (Inst); Mabvax (Inst); Momenta Pharmaceuticals (Inst); OncoMed (Inst)
 
Jeffrey Meyerhardt
No Relationships to Disclose